---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-22-005849"
form_type: "8-K"
ticker: "INSM"
cik: "0001104506"
company_name: "INSMED Inc"
filed_at: "2022-02-17T23:59:59+00:00"
generated_at: "2026-06-27T06:53:52.835091+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Insmed Q4 revenue $56.1M (+36% YoY), net loss $113M; guides 30%+ ARIKAYCE growth in 2022

## Summary
- Full-year 2021 revenue $188.5M (vs $164.4M); ARIKAYCE sales $159.5M US, $16.0M Japan, $12.9M Europe/ROW.
- Net loss for 2021 $434.7M ($3.88/share) vs $294.1M ($3.01/share); Q4 net loss $113.0M ($0.95/share).
- Cash and marketable securities $766.8M; company expects cash runway into 2024.
- Brensocatib Phase 3 ASPEN (bronchiectasis) 50% enrolled; topline data expected early 2023.
- Director Steinar J. Engelsen not standing for re-election at 2022 Annual Meeting; no disagreement.

## SEC filing metadata
- accession: 0001140361-22-005849
- form_type: 8-K
- ticker: INSM
- cik: 0001104506
- company_name: INSMED Inc
- filed_at: 2022-02-17T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1104506/000114036122005849/0001140361-22-005849-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1104506/000114036122005849/brhc10033810_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-22-005849
- JSON: https://secwatch.observer/filing/0001140361-22-005849.json
- Plain text: https://secwatch.observer/filing/0001140361-22-005849.txt

## Key facts
- Executive change
  Steinar J. Engelsen departed as Director at INSMED Inc.
  - Action: not stand for re-election
  - Role: Director
  source text: On February 15, 2022, Steinar J. Engelsen, M.D. notified the board of directors (the “Board”) of the Company that he will not stand for re-election to the Board upon the expiration of his current term as a Class I director, which occurs at the Company’s 2022 Annual Meeting of Shareholders (the “Annual Meeting”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1104506/000114036122005849/0001140361-22-005849-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.